Introduction
Primary hemophagocytic syndromes, which encompass familial hemophagocytic lymphohistiocytosis (FHLH) and, in addition, the immunodeficiencies, Che´diak-Higashi syndrome (CHS), Griscelli syndrome (GS) and X-linked lymphoproliferative syndrome, represent a group of primary immunodeficiencies which have in common profound deficiencies of cytotoxic lymphocyte functions. 1, 2 Although phenotypically different, the common denominator in these disorders is the development of an accelerated phase, characterized by acute, nonremitting systemic inflammatory symptoms, frequently induced by viral infections. [1] [2] [3] [4] Fever, hepatosplenomegaly, neurological symptoms, coagulation abnormalities and blood cytopenias are the characteristics, as are a number of other laboratory abnormalities including hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia and excessively elevated serum levels of proinflammatory cytokines such as IFN-g and tumor necrosis factor-a. Marked hemophagocytosis is usually found in BM and other tissues such as spleen and liver, and infiltration of vital organs including the central nervous system (CNS) by activated CD8-positive T cells and by macrophages is a characteristic histomorphological finding. [4] [5] [6] A number of molecular defects have been detected in affected patients, although in a substantial proportion the underlying defect remains undefined. [7] [8] [9] Treatment by a combination of immunosuppressive agents, usually etoposide (VP-16) and intrathecal MTX as well as antithymocyte globulin (ATG) and CsA, usually leads to control of manifestations of accelerated phases and reinduction of remissions. [10] [11] [12] [13] However, relapses invariably develop and the long-term prognosis in affected patients is fatal unless treated by hematopoietic SCT (HSCT).
14 The curative potential of HSCT was initially demonstrated by Fischer et al., 14 and has subsequently been confirmed by a number of groups. [15] [16] [17] [18] [19] HSCT is currently the only available treatment to cure primary hemophagocytic syndromes and thus represents the treatment of choice in all patients. Interestingly, lasting remissions have also been observed in patients with stable mixed donor-cell chimerism, 19 indicating that even a limited level of immune reconstitution by donor cells is sufficient to control the dysfunctional immune system in patients.
The best results of HSCT have been reported in patients transplanted with inactive disease and this therapy is recommended as soon as a remission is achieved. 11, [15] [16] [17] [18] [19] In patients with active disease due to either incomplete treatment responses or relapses, treatment strategies are not well defined and commonly consist of intensification of immunosuppressive treatment in an attempt to reach a second remission.
In our center, we have performed HSCT in 18 patients with primary hemophagocytic disorders including 5 patients who were not in remission at the time of HSCT. Surprisingly the outcome in the latter patients was not worse compared to patients transplanted in inactive phases of their disorders.
Patients and methods

Patients
Between 1984 and 2006, we transplanted 18 consecutive patients with primary hemophagocytic syndromes. In 10 patients the diagnosis was FHLH, in 3 patients GS and in 5 patients CHS. Patient characteristics are summarized in Table 1 . In the 10 patients with FHLH, a genetic basis was established based on positive family histories with previously affected siblings in 6 patients and/or demonstration of mutations in disease causing genes in 4 patients and in 1 patient on recurrence of accelerated phases. The median age at transplantation was 32 months (range 8-152 months) and the median time from diagnosis to transplantation was 9 months (range 2-68 months).
Informed written consent was provided by parents, and treatment protocols were approved by the institutional ethical committee.
Pre-HSCT therapy and clinical status at HSCT Three patients never experienced an accelerated phase and had not received any treatment before HSCT. The other 15 patients, including all the 10 FHLH patients, had experienced one or more episodes of accelerated phases and were treated according to the multicenter study protocol HLH-94 (consisting of dexamethasone, etoposide, CsA starting week 9; intrathecal MTX if involvement of CNS is there) or HLH-2004 (same regimen as HLH-94 except early use of CsA). 11, 14 Of these 15 patients, 10 were free of clinical and biological manifestations of accelerated phase for at least 4 weeks before transplantation except 2 patients who presented with persistent mild hepatosplenomegaly, but absence of other manifestations. This group of 10 patients, however, was heterogeneous concerning duration of remission, number of previous phases and intensities of proceeding therapies (for details see Table 1 ).
Of the 15 patients, 5 had manifestations of active disease when referred for HSCT. Two had developed findings of recurring accelerated phase during the preceeding 2 weeks and presented with fever, increasing splenomegaly and Table 2 ). The backbone of the conditioning regimen consisted of BU (16 or 20 mg/kg total dose according to age) and CY (200 mg/kg total dose; for details see Table 2 ). In two of the four patients receiving HLA-haploidentical transplants the above conditioning regimen was modified to include fludarabine (160 mg/m 2 total dose) in one and thiotepa (300 mg/m 2 total dose) in the other. In two other children with HLA-nonidentical donors, we used TBI in combination with chemotherapy (for details see Table 2 ).
BM was the source of hematopoietic stem cells in 13 patients and PBSC in 5 patients. Transplants from haploidentical donors were depleted of T cells using the CliniMACS system (Milteny Biotec, Bergisch Gladbach, Germany) to purify CD34 þ cells as previously described. 20 GVHD prophylaxis in the other patients consisted of shortterm MTX (15 mg/m 2 on day 1, and 10 mg/m 2 on days 3 and 6) and CsA for 3-6 months. Four patients received CsA only. ATG was included in the regimen in 13 patients, alternatively Campath1 in 2 and OKT3 in 2 patients. Seattle criteria were used for staging and grading of acute and chronic GVHD. 21, 22 During the more recent period of our study CMV was monitored weekly by measuring pp65 and preemptive virustatic treatment was instituted in patients with positive findings.
Supportive care
Patients were placed in sterile isolators. They received i.v. Ig adapted to keep IgG serum levels above 7 mg/l, and acyclovir if the recipient was serologically positive for herpes simplex virus.
Analysis of chimerism
Chimerism was evaluated in peripheral blood using short tandem repeat analysis with multiple informative alleles. Lineage-specific chimerism was analyzed after selection of CD3 þ , CD15 þ , CD56 þ and CD19 þ cells using the MACs system (Milteny Biotec) as previously described. 20 
Statistical analysis
Statistical analysis was evaluated descriptively as rates or frequencies. P values were analyzed by Fisher's exact test and in an explorative manner.
Results
Engraftment/rejection/chimerism
In the 18 patients a total of 20 transplant procedures were performed, resulting in stable engraftment in 16 cases. Three patients (UPN 33, 274, 560) rejected their grafts, one after a MRD transplant, one after a MUD transplant and the third after a MMRD transplant. In the first patient a second transplant from the same donor was performed at 2 months after the first HSCT, but the patient died 2 weeks later from pseudomonas sepsis. The second patient died at 3 months from CMV infection without a second transplant attempt. The third patient transplanted from MMRD is alive and is well at 18 months after a second HSCT from the same donor (Table 2 ). Of the three other patients receiving HSCT from MMRD (UPN 451, 475, 560), all engrafted but one died at 3 months from CMV infection. Donor-cell chimerism was analyzed in all the surviving patients. In the three patients with MMRD, two show stable mixed and one full donor chimerism. Data on lineage-specific chimerism in these three patients are shown in Table 2 . All patients with matched donors show full donor-cell chimerism.
Treatment-related toxicity and complications Two patients developed severe grade IV (WHO) mucositis.
No patient developed veno-occlusive disease. Acute GVHD of grade II was observed in four patients and of grade III in one patient. It was successfully treated, except in one patient (UPN 526) who developed chronic GVHD of the liver leading to liver failure and death on day 366. Five patients experienced CMV reactivation, of which two succumbed to CMV pneumonitis (UPN 369, 274). Three patients developed an unusual complication at 1-2 months after transplantation consisting, in particular, of high fever, capillary leakage, respiratory distress and hepatic dysfunction, clinically resembling episode of accelerated phases. UPN 185 developed these symptoms on day 35 when an abundance of hemophagocytic cells was noted in his marrow. He died from complications of acute liver dystrophy. UPN 369 similarly developed this abnormality at one month after HSCT and he died of CMVpneumonitis and acute respiratory distress syndrome on day 80. A third patient (UPN 383), who developed this abnormality on day þ 56 in association with an EBV infection, was treated successfully with VP 16 and survives disease free at 7 years after HSCT.
OS and prognostic factors
The OS rate is 72% (13 of 18 patients) with a median follow-up of 4.5 years (range 2-16 years). In patients transplanted from HLA-identical family members, the outcome tended to be better compared to patients undergoing MUD transplants, with survival rates of 83% (5/6) and 63% (5/8), respectively. After HLA-haploidentical transplants, three of the four patients survive.
A number of potentially relevant prognostic factors were analyzed. This included age at HSCT, time interval between diagnosis and HSCT, number of accelerated phase as well as disease status at the time of HSCT. There was a trend that younger age at HSCT correlated with better survival (83% in 6 patients p1 year at HSCT and 67% in 12 patients 41 year; P ¼ 0.61). Survival also tended to be better in patients with short intervals between diagnosis and HSCT (83% in 12 patients with intervals o12 months and 50% in 6 patients with intervals 412 months; P ¼ 0.27).
All the three patients who never had experienced an accelerated phase before HSCT survive and are well, except one who continues to show symptoms of chronic lung disease already present before HSCT. Of the 10 patients who previously had accelerated phases but were in remission at the time of HSCT, 6 (60%) survive, with follow-up ranging from 5 to 13 years. Of the five patients with findings of active disease at the time of HSCT (for details see Patients and methods), four (80%) are long-term survivors, with follow-up ranging from 3 to 18 years. One of these patients suffers from an enteropathy of unknown etiology and all others report a good quality of life. Both surviving patients with active CNS disease at HSCT are free of neurological sequelae.
Discussion
The potential of HSCT to cure primary hemophagocytic syndromes, which include several other primary immunodeficiencies besides FHLH, is firmly established as based on experience reported by a number of groups now. 14, 19, 23 These reports, which predominantly deal with FHLH patients, show survival rates between 45 and 64%, with follow-up in the longest survivors now 410 years. 19 The best results have been obtained in patients transplanted in stable remission, as shown, in particular, in a recent analysis of 48 FHLH patients transplanted in a single center. 19 In this study, surviving rates in patients with stable remission at HSCT was 75% in contrast to a survival rate of 40% in patients transplanted with active disease. There is consent now that HSCT in these patients should be performed early and as soon as a remission has been reached.
It is not uncommon, however, for patients to develop recurrence of active disease by the time a suitable donor is identified, or that the treatment fails to control all aspects of the disease, such as CNS abnormalities. At present the best treatment strategy in this subgroup of patients is not well defined, and commonly reintensification of treatment before HSCT is used in an effort to regain a remission, at the expense of increasing toxic complications. Interestingly, in the single-center study reported here even in this subgroup of patients, the chance of successful transplantation was good, because four of five patients with manifestations of active disease at the time of HSCT are long-term survivors. Our data also indicate that CNS disease may become permanently controlled after successful HSCT. Similar encouraging experience has previously been reported in a study by Du¨rken et al., 24 where all the five FHLH patients with manifestations of active disease survived after HSCT.
In our series, death in two patients was due to CMV pneumonia. This complication has not been observed after introduction of preemptive virustatic treatment in patients with evidence of CMV reactivation, suggesting an advantage of regular CMV monitoring. An unusual complication observed in three cases was compatible with macrophageactivation syndrome. This complication, also referred to as 'hypercytokinemia syndrome', was characterized by nonremitting high fever, hepatic dysfunction and vascular instability with capillary leakage. It was observed in our patients between 4 and 8 weeks after HSCT in the presence of donor-cell engraftment. Others have also reported on the unusual high incidence of this complication in transplanted FHLH patients, indistinguishable from an accelerated phase and thus suggesting recurrence of the disease. 15 Control of this complication requires aggressive management including the use of chemotherapy, as documented in one of our patients who improved dramatically following treatment with VP16 and who is a long-term survivor.
It is likely, that in primary hemophagocytic disorders the success of HSCT is less related to the complete eradication of abnormal cells, that is, proliferating activated CD8-positive T cells, and rather related to the effective and prompt establishment of sufficient regulatory immune functions by donor cells leading to control of the abnormal proliferation of these cells. The poorer prognosis in patients with longer duration of disease and prolonged use of suppressive cytoreductive therapies, as observed in this as well as in other studies, is likely related to accumulated toxicities, infections and organ dysfunctions. This may be different in patients undergoing early HSCT, regardless of the presence of residual disease, where this morbidity may still be limited. As already suggested by Janka 1 and as also emphasized by our findings, HSCT may also be considered in situations where initial therapy fails to control all abnormalities or patients present with early signs of recurrence of disease. It should also be pointed out, that HSCT from HLA-haploidentical donors in our study resulted in correction of the disease in three of four patients, suggesting that the lack of a suitable donor should not preclude patients from being treated early by HSCT.
